Artica Therapeutics

Artica Therapeutics is a Dutch biotechnology company specializing in the development of novel covalent small molecule therapies. The company focuses on targeting G protein-coupled receptors (GPCRs) with 'insurmountable' binding characteristics, designed to potently and selectively inactivate disease-causing proteins for extended periods, even under excessive physiological stimulation. Headquartered in the Leiden Bio Science Park, Artica leverages a proprietary platform that combines covalent chemistry with label-free cellular-based screening. The company's primary mission is to transform the treatment landscape for patients suffering from severe autoimmune and inflammatory disorders by addressing targets previously considered difficult to drug.